LLY

Eli Lilly Hedged Depositary Receipts Stock

StockStock
ISIN: CA28655A1066
Ticker: LLY0
CA28655A1066
LLY0

Price

Historical dividends and forecast

All dividend data

Eli Lilly Hedged Depositary Receipts has so far distributed 0.107 in 2024. The next dividend will be paid on 17.12.2024


0.14

CHART BY

Frequently asked questions

What is Eli Lilly Hedged Depositary Receipts's market capitalization?

The market capitalization of Eli Lilly Hedged Depositary Receipts is $804.85B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Eli Lilly Hedged Depositary Receipts's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Eli Lilly Hedged Depositary Receipts is 91.47. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Eli Lilly Hedged Depositary Receipts?

Eli Lilly Hedged Depositary Receipts's Earnings Per Share (EPS) over the trailing twelve months (TTM) is 9.258. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Eli Lilly Hedged Depositary Receipts's stock?

Currently, 27 analysts cover Eli Lilly Hedged Depositary Receipts's stock, with a consensus target price of $865.62. Analyst ratings provide insights into the stock's expected performance.

What is Eli Lilly Hedged Depositary Receipts's revenue over the trailing twelve months?

Over the trailing twelve months, Eli Lilly Hedged Depositary Receipts reported a revenue of $40.86B.

Is Eli Lilly Hedged Depositary Receipts paying dividends?

Yes, Eli Lilly Hedged Depositary Receipts is paying dividends. The next payment is scheduled for 17.12.2024, with an expected amount of .

What is the EBITDA for Eli Lilly Hedged Depositary Receipts?

Eli Lilly Hedged Depositary Receipts's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $16.11B. EBITDA measures the company's overall financial performance.

What is the free cash flow of Eli Lilly Hedged Depositary Receipts?

Eli Lilly Hedged Depositary Receipts has a free cash flow of -$6.81B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Eli Lilly Hedged Depositary Receipts's stock?

The 5-year beta for Eli Lilly Hedged Depositary Receipts is 0.42. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Eli Lilly Hedged Depositary Receipts have, and what sector and industry does it belong to?

Eli Lilly Hedged Depositary Receipts employs approximately 43,000 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Eli Lilly Hedged Depositary Receipts's shares?

The free float of Eli Lilly Hedged Depositary Receipts is 948.96M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$804.85B

5Y beta

 
0.42

EPS (TTM)

 
9.258

Free Float

 
948.96M

P/E ratio (TTM)

 
91.47

Revenue (TTM)

 
$40.86B

EBITDA (TTM)

 
$16.11B

Free Cashflow (TTM)

 
-$6.81B

Analyst Ratings

The price target is $865.62 and the stock is covered by 27 analysts.

Buy

21

Hold

6

Sell

0

Information

Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. It manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. It is also developing oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).

43,000

Biotechnology & Drugs

Health Care

Identifier

ISIN

CA28655A1066

Primary Ticker

LLY0

Knockouts

Join the conversation